ERBB2 and breast cancer: BC cells are divided into five subtypes, HER2-overexpressing, basal-like, normal-like, luminal A, and luminal B. Due to their different clinicopathological features and prognostics, it is important in identifying candidate miRNAs to distinguish several subtypes for assessing the targeted clinical treatments.